Parkinsonism in patients with a history of amphetamine exposure
Identifieur interne : 001B13 ( Main/Curation ); précédent : 001B12; suivant : 001B14Parkinsonism in patients with a history of amphetamine exposure
Auteurs : Chadwick W. Christine [États-Unis] ; Elisabeth R. Garwood [États-Unis] ; Lauren E. Schrock [États-Unis] ; Daniel E. Austin [États-Unis] ; Charles E. Mcculloch [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2010-01-30.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Adult, Amfetamine, Amphetamine (poisoning), Amphetamine-Related Disorders (epidemiology), Amphetamine-Related Disorders (etiology), Case-Control Studies, Dopamine Agents (poisoning), Environmental Exposure, Female, Follow-Up Studies, Human, Humans, Male, Medical Records, Middle Aged, Nervous system diseases, Neurotoxin, Parkinsonian Disorders (chemically induced), Parkinsonian Disorders (epidemiology), Parkinsonian Disorders (physiopathology), Parkinsonism, Questionnaires, Retrospective Studies, Risk Factors, Time Factors, Vulnerability, neurotoxicant, neurotoxin, selective vulnerability.
- MESH :
- chemical , poisoning : Amphetamine, Dopamine Agents.
- chemically induced : Parkinsonian Disorders.
- epidemiology : Amphetamine-Related Disorders, Parkinsonian Disorders.
- etiology : Amphetamine-Related Disorders.
- physiopathology : Parkinsonian Disorders.
- Adult, Case-Control Studies, Environmental Exposure, Female, Follow-Up Studies, Humans, Male, Medical Records, Middle Aged, Questionnaires, Retrospective Studies, Risk Factors, Time Factors.
Abstract
We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g., manganese), we sought to compare the clinical features of patients with PD with prolonged amphetamine exposure with unexposed patients with PD. Prolonged exposure was defined as a minimum of twice a week for ≥3 months, or weekly use ≥1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine‐exposed group (49.8 ± 8.2 years vs. 53.1 ± 7.4 years; P < 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use. © 2009 Movement Disorder Society
Url:
- https://api.istex.fr/document/13231344BAE719D1985262921EA0739AE1D6AF96/fulltext/pdf
- http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831101
DOI: 10.1002/mds.22915
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000346
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :000346
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000792
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000076
- to stream Pmc, to step Curation: Pour aller vers cette notice dans l'étape Curation :000076
- to stream Pmc, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000319
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001A33
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001A33
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001710
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002969
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :002969
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002969
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :001F49
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A93
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :002226
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000909
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :002496
Links to Exploration step
ISTEX:13231344BAE719D1985262921EA0739AE1D6AF96Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Parkinsonism in patients with a history of amphetamine exposure</title>
<author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W." last="Christine">Chadwick W. Christine</name>
</author>
<author><name sortKey="Garwood, Elisabeth R" sort="Garwood, Elisabeth R" uniqKey="Garwood E" first="Elisabeth R." last="Garwood">Elisabeth R. Garwood</name>
</author>
<author><name sortKey="Schrock, Lauren E" sort="Schrock, Lauren E" uniqKey="Schrock L" first="Lauren E." last="Schrock">Lauren E. Schrock</name>
</author>
<author><name sortKey="Austin, Daniel E" sort="Austin, Daniel E" uniqKey="Austin D" first="Daniel E." last="Austin">Daniel E. Austin</name>
</author>
<author><name sortKey="Mcculloch, Charles E" sort="Mcculloch, Charles E" uniqKey="Mcculloch C" first="Charles E." last="Mcculloch">Charles E. Mcculloch</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:13231344BAE719D1985262921EA0739AE1D6AF96</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1002/mds.22915</idno>
<idno type="url">https://api.istex.fr/document/13231344BAE719D1985262921EA0739AE1D6AF96/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000346</idno>
<idno type="wicri:Area/Istex/Curation">000346</idno>
<idno type="wicri:Area/Istex/Checkpoint">000792</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Christine C:parkinsonism:in:patients</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831101</idno>
<idno type="RBID">PMC:2831101</idno>
<idno type="wicri:Area/Pmc/Corpus">000076</idno>
<idno type="wicri:Area/Pmc/Curation">000076</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000319</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">001A33</idno>
<idno type="wicri:Area/PubMed/Curation">001A33</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001710</idno>
<idno type="wicri:Area/Ncbi/Merge">002969</idno>
<idno type="wicri:Area/Ncbi/Curation">002969</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002969</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Christine C:parkinsonism:in:patients</idno>
<idno type="wicri:Area/Main/Merge">001F49</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:10-0303293</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A93</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002226</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000909</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Christine C:parkinsonism:in:patients</idno>
<idno type="wicri:Area/Main/Merge">002496</idno>
<idno type="wicri:Area/Main/Curation">001B13</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Parkinsonism in patients with a history of amphetamine exposure</title>
<author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W." last="Christine">Chadwick W. Christine</name>
<affiliation wicri:level="2"><country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Department of Neurology, University of California, San Francisco</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Garwood, Elisabeth R" sort="Garwood, Elisabeth R" uniqKey="Garwood E" first="Elisabeth R." last="Garwood">Elisabeth R. Garwood</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Pennsylvania State University College of Medicine, Hershey</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Schrock, Lauren E" sort="Schrock, Lauren E" uniqKey="Schrock L" first="Lauren E." last="Schrock">Lauren E. Schrock</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Utah</region>
</placeName>
<wicri:cityArea>Department of Neurology, University of Utah, Salt Lake City</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Austin, Daniel E" sort="Austin, Daniel E" uniqKey="Austin D" first="Daniel E." last="Austin">Daniel E. Austin</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maine (État)</region>
</placeName>
<wicri:cityArea>Colby College, Waterville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mcculloch, Charles E" sort="Mcculloch, Charles E" uniqKey="Mcculloch C" first="Charles E." last="Mcculloch">Charles E. Mcculloch</name>
<affiliation wicri:level="2"><country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Department of Epidemiology and Biostatistics, University of California, San Francisco</wicri:cityArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-01-30">2010-01-30</date>
<biblScope unit="vol">25</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="228">228</biblScope>
<biblScope unit="page" to="231">231</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">13231344BAE719D1985262921EA0739AE1D6AF96</idno>
<idno type="DOI">10.1002/mds.22915</idno>
<idno type="ArticleID">MDS22915</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Amfetamine</term>
<term>Amphetamine (poisoning)</term>
<term>Amphetamine-Related Disorders (epidemiology)</term>
<term>Amphetamine-Related Disorders (etiology)</term>
<term>Case-Control Studies</term>
<term>Dopamine Agents (poisoning)</term>
<term>Environmental Exposure</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Human</term>
<term>Humans</term>
<term>Male</term>
<term>Medical Records</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Neurotoxin</term>
<term>Parkinsonian Disorders (chemically induced)</term>
<term>Parkinsonian Disorders (epidemiology)</term>
<term>Parkinsonian Disorders (physiopathology)</term>
<term>Parkinsonism</term>
<term>Questionnaires</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
<term>Time Factors</term>
<term>Vulnerability</term>
<term>neurotoxicant</term>
<term>neurotoxin</term>
<term>selective vulnerability</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="poisoning" xml:lang="en"><term>Amphetamine</term>
<term>Dopamine Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Amphetamine-Related Disorders</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Amphetamine-Related Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Case-Control Studies</term>
<term>Environmental Exposure</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Medical Records</term>
<term>Middle Aged</term>
<term>Questionnaires</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Amfétamine</term>
<term>Homme</term>
<term>Neurotoxine</term>
<term>Parkinsonisme</term>
<term>Pathologie du système nerveux</term>
<term>Vulnérabilité</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g., manganese), we sought to compare the clinical features of patients with PD with prolonged amphetamine exposure with unexposed patients with PD. Prolonged exposure was defined as a minimum of twice a week for ≥3 months, or weekly use ≥1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine‐exposed group (49.8 ± 8.2 years vs. 53.1 ± 7.4 years; P < 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use. © 2009 Movement Disorder Society</div>
</front>
</TEI>
<double idat="0885-3185:2010:Christine C:parkinsonism:in:patients"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Parkinsonism in Patients with a History of Amphetamine Exposure</title>
<author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W." last="Christine">Chadwick W. Christine</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, University of California</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Garwood, Elisabeth R" sort="Garwood, Elisabeth R" uniqKey="Garwood E" first="Elisabeth R." last="Garwood">Elisabeth R. Garwood</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Pennsylvania State University College of Medicine</s1>
<s2>Hershey, Pennsylvania</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Schrock, Lauren E" sort="Schrock, Lauren E" uniqKey="Schrock L" first="Lauren E." last="Schrock">Lauren E. Schrock</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Neurology, University of Utah</s1>
<s2>Salt Lake City, Utah</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Utah</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Austin, Daniel E" sort="Austin, Daniel E" uniqKey="Austin D" first="Daniel E." last="Austin">Daniel E. Austin</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Colby College</s1>
<s2>Waterville, Maine</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maine (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mcculloch, Charles E" sort="Mcculloch, Charles E" uniqKey="Mcculloch C" first="Charles E." last="Mcculloch">Charles E. Mcculloch</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Department of Epidemiology and Biostatistics, University of California</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0303293</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0303293 INIST</idno>
<idno type="RBID">Pascal:10-0303293</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A93</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002226</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000909</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Christine C:parkinsonism:in:patients</idno>
<idno type="wicri:Area/Main/Merge">002496</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Parkinsonism in Patients with a History of Amphetamine Exposure</title>
<author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W." last="Christine">Chadwick W. Christine</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurology, University of California</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Garwood, Elisabeth R" sort="Garwood, Elisabeth R" uniqKey="Garwood E" first="Elisabeth R." last="Garwood">Elisabeth R. Garwood</name>
<affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Pennsylvania State University College of Medicine</s1>
<s2>Hershey, Pennsylvania</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Schrock, Lauren E" sort="Schrock, Lauren E" uniqKey="Schrock L" first="Lauren E." last="Schrock">Lauren E. Schrock</name>
<affiliation wicri:level="2"><inist:fA14 i1="03"><s1>Department of Neurology, University of Utah</s1>
<s2>Salt Lake City, Utah</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Utah</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Austin, Daniel E" sort="Austin, Daniel E" uniqKey="Austin D" first="Daniel E." last="Austin">Daniel E. Austin</name>
<affiliation wicri:level="2"><inist:fA14 i1="04"><s1>Colby College</s1>
<s2>Waterville, Maine</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Maine (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mcculloch, Charles E" sort="Mcculloch, Charles E" uniqKey="Mcculloch C" first="Charles E." last="Mcculloch">Charles E. Mcculloch</name>
<affiliation wicri:level="2"><inist:fA14 i1="05"><s1>Department of Epidemiology and Biostatistics, University of California</s1>
<s2>San Francisco, California</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amfetamine</term>
<term>Human</term>
<term>Nervous system diseases</term>
<term>Neurotoxin</term>
<term>Parkinsonism</term>
<term>Vulnerability</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinsonisme</term>
<term>Pathologie du système nerveux</term>
<term>Homme</term>
<term>Amfétamine</term>
<term>Neurotoxine</term>
<term>Vulnérabilité</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g., manganese), we sought to compare the clinical features of PD patients with prolonged amphetamine exposure with unexposed PD patients methcathinone. Prolonged exposure was defined as a minimum of twice a week for ≥3 months, or weekly use ≥1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine-exposed group (49.8 ± 8.2 years vs. 53.1 ± 7.4 years; P < 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use.</div>
</front>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Parkinsonism in patients with a history of amphetamine exposure</title>
<author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W." last="Christine">Chadwick W. Christine</name>
</author>
<author><name sortKey="Garwood, Elisabeth R" sort="Garwood, Elisabeth R" uniqKey="Garwood E" first="Elisabeth R." last="Garwood">Elisabeth R. Garwood</name>
</author>
<author><name sortKey="Schrock, Lauren E" sort="Schrock, Lauren E" uniqKey="Schrock L" first="Lauren E." last="Schrock">Lauren E. Schrock</name>
</author>
<author><name sortKey="Austin, Daniel E" sort="Austin, Daniel E" uniqKey="Austin D" first="Daniel E." last="Austin">Daniel E. Austin</name>
</author>
<author><name sortKey="Mcculloch, Charles E" sort="Mcculloch, Charles E" uniqKey="Mcculloch C" first="Charles E." last="Mcculloch">Charles E. Mcculloch</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:13231344BAE719D1985262921EA0739AE1D6AF96</idno>
<date when="2010" year="2010">2010</date>
<idno type="doi">10.1002/mds.22915</idno>
<idno type="url">https://api.istex.fr/document/13231344BAE719D1985262921EA0739AE1D6AF96/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000346</idno>
<idno type="wicri:Area/Istex/Curation">000346</idno>
<idno type="wicri:Area/Istex/Checkpoint">000792</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Christine C:parkinsonism:in:patients</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831101</idno>
<idno type="RBID">PMC:2831101</idno>
<idno type="wicri:Area/Pmc/Corpus">000076</idno>
<idno type="wicri:Area/Pmc/Curation">000076</idno>
<idno type="wicri:Area/Pmc/Checkpoint">000319</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">001A33</idno>
<idno type="wicri:Area/PubMed/Curation">001A33</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001710</idno>
<idno type="wicri:Area/Ncbi/Merge">002969</idno>
<idno type="wicri:Area/Ncbi/Curation">002969</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">002969</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Christine C:parkinsonism:in:patients</idno>
<idno type="wicri:Area/Main/Merge">001F49</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Parkinsonism in patients with a history of amphetamine exposure</title>
<author><name sortKey="Christine, Chadwick W" sort="Christine, Chadwick W" uniqKey="Christine C" first="Chadwick W." last="Christine">Chadwick W. Christine</name>
<affiliation wicri:level="2"><country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Department of Neurology, University of California, San Francisco</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Garwood, Elisabeth R" sort="Garwood, Elisabeth R" uniqKey="Garwood E" first="Elisabeth R." last="Garwood">Elisabeth R. Garwood</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Pennsylvanie</region>
</placeName>
<wicri:cityArea>Pennsylvania State University College of Medicine, Hershey</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Schrock, Lauren E" sort="Schrock, Lauren E" uniqKey="Schrock L" first="Lauren E." last="Schrock">Lauren E. Schrock</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Utah</region>
</placeName>
<wicri:cityArea>Department of Neurology, University of Utah, Salt Lake City</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Austin, Daniel E" sort="Austin, Daniel E" uniqKey="Austin D" first="Daniel E." last="Austin">Daniel E. Austin</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Maine (État)</region>
</placeName>
<wicri:cityArea>Colby College, Waterville</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mcculloch, Charles E" sort="Mcculloch, Charles E" uniqKey="Mcculloch C" first="Charles E." last="Mcculloch">Charles E. Mcculloch</name>
<affiliation wicri:level="2"><country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Department of Epidemiology and Biostatistics, University of California, San Francisco</wicri:cityArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2010-01-30">2010-01-30</date>
<biblScope unit="vol">25</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="228">228</biblScope>
<biblScope unit="page" to="231">231</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">13231344BAE719D1985262921EA0739AE1D6AF96</idno>
<idno type="DOI">10.1002/mds.22915</idno>
<idno type="ArticleID">MDS22915</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Amphetamine (poisoning)</term>
<term>Amphetamine-Related Disorders (epidemiology)</term>
<term>Amphetamine-Related Disorders (etiology)</term>
<term>Case-Control Studies</term>
<term>Dopamine Agents (poisoning)</term>
<term>Environmental Exposure</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Medical Records</term>
<term>Middle Aged</term>
<term>Parkinsonian Disorders (chemically induced)</term>
<term>Parkinsonian Disorders (epidemiology)</term>
<term>Parkinsonian Disorders (physiopathology)</term>
<term>Questionnaires</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
<term>Time Factors</term>
<term>neurotoxicant</term>
<term>neurotoxin</term>
<term>selective vulnerability</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="poisoning" xml:lang="en"><term>Amphetamine</term>
<term>Dopamine Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Amphetamine-Related Disorders</term>
<term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Amphetamine-Related Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Case-Control Studies</term>
<term>Environmental Exposure</term>
<term>Female</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Medical Records</term>
<term>Middle Aged</term>
<term>Questionnaires</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
<term>Time Factors</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We recently found a higher rate of prolonged amphetamine exposure in patients diagnosed with Parkinson's disease (PD) than in spouse/caregiver controls. Since distinguishing features have been described in some patients with parkinsonism due to environment exposures (e.g., manganese), we sought to compare the clinical features of patients with PD with prolonged amphetamine exposure with unexposed patients with PD. Prolonged exposure was defined as a minimum of twice a week for ≥3 months, or weekly use ≥1 year. We reviewed the clinical records of patients with PD who had participated in a telephone survey of drug and environmental exposures and compared the clinical features of patients with a history of prolonged amphetamine exposure to patients who had no such exposure. Records were available for 16 of 17 (94%) patients with prior amphetamine exposure and 127 of 137 (92%) of those unexposed. Age at diagnosis was younger in the amphetamine‐exposed group (49.8 ± 8.2 years vs. 53.1 ± 7.4 years; P < 0.05), but other features, including presenting symptoms, initial and later treatments, development of motor fluctuations, and MRI findings were similar between these groups. Because we did not detect clinical features that differentiate parkinsonism in patients with prolonged amphetamine exposure, research to determine whether amphetamine exposure is a risk factor for parkinsonism will require detailed histories of medication and recreational drug use. © 2009 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B13 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001B13 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:13231344BAE719D1985262921EA0739AE1D6AF96 |texte= Parkinsonism in patients with a history of amphetamine exposure }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |